DOCSLIB.ORG

Anti-Infective Drug Poster

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Anti-Infective Drug Poster Anti-Infective Drugs Created by the Njardarson Group (The University of Arizona): Edon Vitaku, Elizabeth A. Ilardi, Daniel J. Mack, Monica A. Fallon, Erik B. Gerlach, Miyant’e Y. Newton, Angela N. Yazzie, Jón T. Njarðarson Streptozol Spectam Novocain Sulfadiazine M&B Streptomycin Chloromycetin Terramycin Tetracyn Seromycin Tubizid Illosone Furadantin Ethina Vancocin Polymyxin E Viderabin Declomycin Sulfamethizole Blephamide S.O.P. ( Sulfanilamide ) ( Spectinomycin ) ( Procaine ) ( Sulfadiazine ) ( Sulfapyridine ) ( Streptomycin ) ( Chloramphenicol ) ( Oxytetracycline ) ( Tetracycline ) ( Cycloserine ) ( Isoniazid ) ( Erythromycin ) ( Nitrofurantoin ) ( Ethionamide ) ( Vancomycin ) ( Colistin ) ( Vidarabine ) ( Demeclocycline ) ( Sulfamethizole ) ( Prednisolone Acetate & Sulfacetamide ) ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIMYCOBACTERIAL ANTIMYCOBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIMYCOBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIVIRAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL Approved 1937 Approved 1937 Approved 1939 Approved 1941 Approved 1942 Approved 1946 Approved 1949 Approved 1950 Approved 1950s Approved 1950s Approved 1952 Approved 1953 Approved 1953 Approved 1956 Approved 1958 Approved 1959 Approved 1960 Approved 1960 Approved 1960s Approved 1961 Coly-Mycin S Caprocin Poly-Pred Aureocarmyl Stoxil Flagyl NegGram Neomycin Flumadine Omnipen Neosporin G.U. Clomocycline Versapen-K Fungizone Vibramycin Myambutol Pathocil Cleocin Gentak Floxapen ( Neomycin, Colistin, Hydrocortisone Acetate & Thonzonium ) ( Capreomycin ) ( Neomycin, Polymyxin B & Prednisolone Acetate ) ( Lymecycline ) ( Idoxuridine ) ( Metronidazole ) ( Nalidixic Acid ) ( Neomycin ) ( Rimantadine ) ( Ampicillin ) ( Neomycin & Polymyxin B ) ( Clomocycline ) ( Hetacillin ) ( Amphotericin B ) ( Doxycycline ) ( Ethambutol ) ( Dicloxacillin ) ( Clindamycin ) ( Gentamicin ) ( Flucloxacillin ) ANTIBACTERIAL ANTIMYCOBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIVIRAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIVIRAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIMYCOTIC ANTIBACTERIAL ANTIMYCOBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL Approved 1962 Approved 1962 Approved 1963 Approved 1963 Approved 1963 Approved 1963 Approved 1964 Approved 1964 Approved 1965 Approved 1965 Approved 1966 Approved 1966 Approved 1966 Approved 1966 Approved 1967 Approved 1967 Approved 1968 Approved 1970 Approved 1970 Approved 1970s Keflex Oxacillin Minocin Veetids Pyrazinamide Ancobon Bactrim Kantrex Trimox Cloxapen Monistat 7 Rifamate Nebcin Geocillin Duricef Ceclor Dapsone Cinobac Proloprim Pipracil ( Cephalexin ) ( Oxacillin ) ( Minocycline ) ( Penicillin V ) ( Pyrazinamide ) ( Flucytosine ) ( Trimethoprim & Sulfamethoxazole ) ( Kanamycin ) ( Amoxicillin ) ( Cloxacillin ) ( Miconazole ) ( Isoniazid & Rifampin ) ( Tobramycin ) ( Carbenicillin ) ( Cefadroxil ) ( Cefaclor ) ( Dapsone ) ( Cinoxacin ) ( Trimethoprim ) ( Piperacillin ) ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIMYCOBACTERIAL ANTIMYCOTIC ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIMYCOTIC ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIMYCOBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL Approved 1971 Approved 1971 Approved 1971 Approved 1971 Approved 1971 Approved 1971 Approved 1973 Approved 1973 Approved 1974 Approved 1974 Approved 1974 Approved 1975 Approved 1975 Approved 1977 Approved 1978 Approved 1979 Approved 1979 Approved 1980 Approved 1980 Approved 1981 Claforan Nizoral Amikin Mezlin Sulfamethoxazole Aziocillin Polymyxin B Netromycin Zinacef Precef Rocephin Primaxin Timentin Fortaz Pefloxacine Rulid Virazole Unasyn Azactam Noroxin ( Cefotaxime ) ( Ketoconazole ) ( Amikacin ) ( Mezlocillin ) ( Sulfamethoxazole ) ( Azlocillin ) ( Polymyxin B ) ( Netilmicin ) ( Cefuroxime ) ( Ceforanide ) ( Ceftriaxone ) ( Cilastatin & Imipenem ) ( Clavulanate & Ticarcillin ) ( Ceftazidime ) ( Pefloxacin ) ( Roxithromycin ) ( Ribavirin ) ( Sulbactam & Ampicillin ) ( Aztreonam ) ( Norfloxacin ) ANTIBACTERIAL ANTIMYCOTIC ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIVIRAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL Approved 1981 Approved 1981 Approved 1981 Approved 1982 Approved 1982 Approved 1982 Approved 1983 Approved 1983 Approved 1983 Approved 1984 Approved 1984 Approved 1985 Approved 1985 Approved 1985 Approved 1985 Approved 1985 Approved 1985 Approved 1986 Approved 1986 Approved 1986 Lamprene Cefmax Retrovir Cipro Neosporin Pred-G Polytrim Ceradon Penicillin G Zefazone Cefpiramide Suprax Cytovene Diflucan Floxin Zithromax Lorabid Penetrex Biaxin Videx ( Clofazimine ) ( Cefmenoxime ) ( Zidovudine ) ( Ciprofloxacin ) ( Neomycin, Polymyxin B & Gramicidin ) ( Gentamicin & Prednisolone Acetate ) ( Trimethoprim & Polymyxin B ) ( Cefotiam ) ( Penicillin G ) ( Cefmetazole ) ( Cefpiramide ) ( Cefixime ) ( Ganciclovir ) ( Fluconazole ) ( Ofloxacin ) ( Azithromycin ) ( Loracarbef ) ( Enoxacin ) ( Clarithromycin ) ( Didanosine ) ANTIMYCOBACTERIAL ANTIBACTERIAL ANTIVIRAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIVIRAL ANTIMYCOTIC ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIVIRAL Approved 1986 Approved 1987 Approved 1987 Approved 1987 Approved 1987 Approved 1988 Approved 1988 Approved 1988 Approved 1988 Approved 1989 Approved 1989 Approved 1989 Approved 1989 Approved 1990 Approved 1990 Approved 1991 Approved 1991 Approved 1991 Approved 1991 Approved 1991 Cefzil Foscavir Maxaquin Mycobutin HIVID Sporanox Zosyn Rifater Paser Zerit Famvir Dynabac Epivir Invirase Merrem Monurol Levaquin Zagam Crixivan Viramune ( Cefprozil ) ( Foscarnet ) ( Lomefloxacin ) ( Rifabutin ) ( Zalcitabine ) ( Itraconazole ) ( Piperacillin & Tazobactam ) ( Isoniazid, Pyrazinamide & Rifampin ) ( Aminosalicylic Acid ) ( Stavudine ) ( Famciclovir ) ( Dirithromycin ) ( Lamivudine ) ( Saquinavir ) ( Meropenem ) ( Fosfomycin ) ( Levofloxacin ) ( Sparfloxacin ) ( Indinavir ) ( Nevirapine ) ANTIBACTERIAL ANTIVIRAL ANTIBACTERIAL ANTIMYCOBACTERIAL ANTIVIRAL ANTIMYCOTIC ANTIBACTERIAL ANTIBACTERIAL ANTIMYCOBACTERIAL ANTIVIRAL ANTIVIRAL ANTIBACTERIAL ANTIVIRAL ANTIVIRAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIVIRAL ANTIVIRAL Approved 1991 Approved 1991 Approved 1992 Approved 1992 Approved 1992 Approved 1992 Approved 1993 Approved 1994 Approved 1994 Approved 1994 Approved 1994 Approved 1995 Approved 1995 Approved 1995 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Denavir Vistide Norvir Prevpac Raxar Omnicef Viracept Rescriptor Trovan Combivir Priftin Ziagen Sustiva Relenza Avelox Tamiflu Agenerase Zyvox Trizivir Kaletra ( Penciclovir ) ( Cidofovir ) ( Ritonavir ) ( Amoxicillin, Clarithromycin & Lansoprazole ) ( Grepafloxacin ) ( Cefdinir ) ( Nelfinavir ) ( Delavirdine ) ( Trovafloxacin ) ( Lamivudine & Zidovudine ) ( Rifapentine ) ( Abacavir ) ( Efavirenz ) ( Zanamivir ) ( Moxifloxacin ) ( Oseltamivir ) ( Amprenavir ) ( Linezolid ) ( Abacavir, Lamivudine & Zidovudine ) ( Lopinavir & Ritonavir ) ANTIVIRAL ANTIVIRAL ANTIVIRAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIVIRAL ANTIVIRAL ANTIBACTERIAL ANTIVIRAL ANTIMYCOBACTERIAL ANTIVIRAL ANTIVIRAL ANTIVIRAL ANTIBACTERIAL ANTIVIRAL ANTIVIRAL ANTIBACTERIAL ANTIVIRAL ANTIVIRAL Approved 1996 Approved 1996 Approved 1996 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1998 Approved 1998 Approved 1998 Approved 1999 Approved 1999 Approved 1999 Approved 1999 Approved 2000 Approved 2000 Approved 2000 Spectracef Cancidas INVanz Viread Vfend Hepsera Augmentin XR Zymar Factive Emtriva Reyataz Ketek Tindamax Epzicom Truvada Mycamine Baraclude Aptivus Eraxis Atripla ( Cefditoren Pivoxil ) ( Caspofungin ) ( Ertapenem ) ( Tenofovir ) ( Voriconazole ) ( Adefovir Dipivoxil ) ( Amoxicillin & Clavulanate ) ( Gatifloxacin ) ( Gemifloxacin ) ( Emtricitabine ) ( Atazanavir ) ( Telithromycin ) ( Tinidazole ) ( Abacavir & Lamivudine ) ( Emtricitabine & Tenofovir Disoproxil ) ( Micafungin ) ( Entecavir ) ( Tipranavir ) ( Anidulafungin ) ( Emtricitabine, Tenofovir Disoproxil & Efavirenz ) ANTIBACTERIAL ANTIMYCOTIC ANTIBACTERIAL ANTIVIRAL ANTIMYCOTIC ANTIVIRAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIVIRAL ANTIVIRAL ANTIBACTERIAL ANTIBACTERIAL ANTIVIRAL ANTIVIRAL ANTIMYCOTIC ANTIVIRAL ANTIVIRAL ANTIMYCOTIC ANTIVIRAL Approved 2001 Approved 2001 Approved 2001 Approved 2001 Approved 2002 Approved 2002 Approved 2002 Approved 2003 Approved 2003 Approved 2003 Approved 2003 Approved 2004 Approved 2004 Approved 2004 Approved 2004 Approved 2005 Approved 2005 Approved 2005 Approved 2006 Approved 2006 Isentress Selzentry Intelence Viread Besivance Vibativ Teflaro Natroba Victrelis Edurant Incivek Dificid Complera Stribild Sirturo Fulyzaq ( Raltegravir ) ( Maraviroc ) ( Etravirine ) ( Tenofovir Disoproxil ) ( Besifloxacin ) ( Telavancin ) ( Ceftaroline Fosamil ) ( Spinosad ) ( Boceprevir ) ( Rilpivirine ) ( Telaprevir ) ( Fidaxomicin ) ( Emtricitabine, Rilpivirine & Tenofovir Disoproxil ) ( Cobicistat, Elvitegravir, Emtricitabine & Tenofovir Disoproxil ) ( Bedaquiline ) ( Crofelemer ) ANTIVIRAL ANTIVIRAL ANTIVIRAL ANTIVIRAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIVIRAL ANTIVIRAL ANTIVIRAL ANTIBACTERIAL ANTIVIRAL ANTIVIRAL ANTIBACTERIAL ANTIBACTERIAL Approved 2007 Approved 2007 Approved 2008 Approved 2008 Approved 2009 Approved 2009 Approved 2010 Approved 2011 Approved 2011 Approved 2011 Approved 2011 Approved 2011 Approved 2011 Approved 2012 Approved 2012 Approved 2012 All drugs are considered FDA approved in the U.S. following the passage of the Pure Food and Drugs Act in 1906. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/.
Load more

Recommended publications
  • Cefditoren Pivoxil) Tablets 200 and 400 Mg
    SPECTRACEF® (cefditoren pivoxil) Tablets 200 and 400 mg. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION SPECTRACEF® tablets contain cefditoren pivoxil, a semi-synthetic cephalosporin antibiotic for oral administration. It is a prodrug which is hydrolyzed by esterases during absorption, and the drug is distributed in the circulating blood as active cefditoren. Chemically, cefditoren pivoxil is (-)-(6R,7R)-2,2-dimethylpropionyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxy­ iminoacetamido]-3-[(Z)-2-(4-methylthiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate. The empirical formula is C25H28N6O7S3 and the molecular weight is 620.73. The structural formula of cefditoren pivoxil is shown below: cefditoren pivoxil The amorphous form of cefditoren pivoxil developed for clinical use is a light yellow powder. It is freely soluble in dilute hydrochloric acid and soluble at levels equal to 6.06 mg/mL in ethanol and <0.1 mg/mL in water. SPECTRACEF® (cefditoren pivoxil) tablets contain 200 mg or 400 mg of cefditoren as cefditoren pivoxil and the following inactive ingredients: croscarmellose sodium, D-mannitol, hydroxypropyl cellulose, hypromellose, magnesium stearate, sodium caseinate (a milk protein), and sodium tripolyphosphate. The tablet coating contains carnauba wax, hypromellose, polyethylene glycol, and titanium dioxide. Tablets are printed with ink containing D&C Red No. 27, FD&C Blue No. 1, propylene glycol, and shellac. CLINICAL PHARMACOLOGY Pharmacokinetics Absorption Oral Bioavailability Following oral administration, cefditoren pivoxil is absorbed from the gastrointestinal tract and hydrolyzed to cefditoren by esterases.
    [Show full text]
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application
    Infect Dis Ther (2017) 6:57–67 DOI 10.1007/s40121-016-0144-8 REVIEW Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application Juwon Yim . Leah M. Molloy . Jason G. Newland Received: November 10, 2016 / Published online: December 30, 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and Ceftaroline is a novel cephalosporin recently resistant Gram-positive infections that fail approved in children for treatment of acute first-line antimicrobial agents. However, bacterial skin and soft tissue infections and limited data are available on tolerability in community-acquired bacterial pneumonia neonates and infants younger than 2 months (CABP) caused by methicillin-resistant of age, and on pharmacokinetic characteristics Staphylococcus aureus, Streptococcus pneumoniae in children with chronic medical conditions and other susceptible bacteria. With a favorable and those with invasive, complicated tolerability profile and efficacy proven in infections. In this review, the microbiological pediatric patients and excellent in vitro profile of ceftaroline, its mechanism of action, activity against resistant Gram-positive and and pharmacokinetic profile will be presented. Gram-negative bacteria, ceftaroline may serve Additionally, clinical evidence for use in as a therapeutic option for polymicrobial pediatric patients and proposed place in therapy is discussed. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1F47F0601BB3F2DD. Keywords: Antibiotic resistance; Ceftaroline J. Yim (&) fosamil; Children; Methicillin-resistant St. John Hospital and Medical Center, Detroit, MI, Staphylococcus aureus; Streptococcus pneumoniae USA e-mail: [email protected] L.
    [Show full text]
  • Derivatives of Clavulanic Acid, Process for Their Preparation And
    Europaisches Patentamt © ê European Patent Office © Publication number: 0 003 254 Office européen des brevets Bl © EUROPEAN PATENT SPECIFICATION (45) Date of publication of patent spécification: 28.03.84 © Int. ci.3: C 07 D 498/04, A 61 K 31/42, @ Application number: 78300762.8 A 61 K 31/43, @ Date offiling: 07.12.78 A 61 K 31/545 //(C07D498/04, 263/00, 205/00), (A6 1 K3 1 /43, 3 1/42), (A61K3 1/545, 31/42) (54) Derivatives of clavulanic acid, process for their préparation and compositions containing them. (§) Priority: 26.01 .78 GB 312978 @ Proprietor: BEECHAM GROUP PLC Beecham House Great West Road Brentford Middlesex (GB) (43) Date of publication of application: 08.08.79 Bulletin 79/1 6 @ Inventor: Gasson, Brian Charles 9, Clarence Walk (45) Publication of the grant of the patent: Redhill Surrey (GB) 28.03.84 Bulletin 84/13 © Représentative: Hesketh, Alan, Dr. et al, (84) Designated Contracting States: European Patent Attorney Beecham BE CH DEFRGBITNL Pharmaceuticals Great Burgh Yew Tree Bottom Road Epsom, Surrey, KT18 5XQ (GB) (56) Références cited: BE - A - 847 046 The file contains technical information submitted after the application was filed and not included in this spécification Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid.
    [Show full text]
  • Crofelemer Oral Delayed Release Tablet
    Contains Nonbinding Recommendations Draft – Not for Implementation Draft Guidance on Crofelemer This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Crofelemer Dosage Form; Route: Tablet, delayed release; oral Strength: 125 mg Recommendations for the Assessment of Identity and Quality of Botanical Raw Material (BRM): Crofelemer is a botanical drug derived from BRM, the crude red latex of Croton lechleri Müll. Arg. [Fam. Euphorbiacae], which is also called dragon’s blood (sangre de drago). Generic drug applicants should use the same plant species and perform BRM assessment: 1. Crofelemer BRM should be collected from the crude red latex of Croton lechleri. The plant species should be correctly identified and authenticated based on techniques such as macroscopic/microscopic and/or analysis of genetic material. 2. Crude red latex as BRM should be collected from the mature tree with defined eco- geographic regions (EGRs). Implementing and enforcing established good agricultural and collection practice (GACP) procedures will minimize variations in BRM and ensure batch- to-batch consistency of crofelemer. 3. BRMs should be analyzed for their crofelemer content, total phenolics and taspine content, as well as heavy metals and pesticides. Recommendations for Demonstrating API Sameness: API sameness can be established by showing equivalence between Test API and API from the reference listed drug (RLD) product with the three criteria described in detail below.
    [Show full text]
  • A TWO-YEAR RETROSPECTIVE ANALYSIS of ADVERSE DRUG REACTIONS with 5PSQ-031 FLUOROQUINOLONE and QUINOLONE ANTIBIOTICS 24Th Congress Of
    A TWO-YEAR RETROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTIONS WITH 5PSQ-031 FLUOROQUINOLONE AND QUINOLONE ANTIBIOTICS 24th Congress of V. Borsi1, M. Del Lungo2, L. Giovannetti1, M.G. Lai1, M. Parrilli1 1 Azienda USL Toscana Centro, Pharmacovigilance Centre, Florence, Italy 2 Dept. of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), 27-29 March 2019 Section of Pharmacology and Toxicology , University of Florence, Italy BACKGROUND PURPOSE On 9 February 2017, the Pharmacovigilance Risk Assessment Committee (PRAC) initiated a review1 of disabling To review the adverse drugs and potentially long-lasting side effects reported with systemic and inhaled quinolone and fluoroquinolone reactions (ADRs) of antibiotics at the request of the German medicines authority (BfArM) following reports of long-lasting side effects systemic and inhaled in the national safety database and the published literature. fluoroquinolone and quinolone antibiotics that MATERIAL AND METHODS involved peripheral and central nervous system, Retrospective analysis of ADRs reported in our APVD involving ciprofloxacin, flumequine, levofloxacin, tendons, muscles and joints lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, cinoxacin, nalidixic acid, reported from our pipemidic given systemically (by mouth or injection). The period considered is September 2016 to September Pharmacovigilance 2018. Department (PVD). RESULTS 22 ADRs were reported in our PVD involving fluoroquinolone and quinolone antibiotics in the period considered and that affected peripheral or central nervous system, tendons, muscles and joints. The mean patient age was 67,3 years (range: 17-92 years). 63,7% of the ADRs reported were serious, of which 22,7% caused hospitalization and 4,5% caused persistent/severe disability. 81,8% of the ADRs were reported by a healthcare professional (physician, pharmacist or other) and 18,2% by patient or a non-healthcare professional.
    [Show full text]
  • Virtual Screening of Inhibitors Against Envelope Glycoprotein of Chikungunya Virus: a Drug Repositioning Approach
    www.bioinformation.net Research Article Volume 15(6) Virtual screening of inhibitors against Envelope glycoprotein of Chikungunya Virus: a drug repositioning approach Garima Agarwal1, Sanjay Gupta1, Reema Gabrani1, Amita Gupta2, Vijay Kumar Chaudhary2, Vandana Gupta3* 1Center for Emerging Diseases, Department of Biotechnology, Jaypee Institute of Information Technology, Noida, UP 201309, India: 2Centre for Innovation in Infectious Disease Research, Education and Training, University of Delhi South Campus, Benito Juarez Marg, New Delhi 110021, India: 3Department of Microbiology, Ram Lal Anand College, University of Delhi South Campus (UDSC), Benito Juarez Marg, New Delhi 110021, India. Vandana Gupta – E-mail: [email protected]; Phone: +91 7838004880 Received April 1, 2019; Accepted April 16, 2019; Published June 15, 2019 DOI: 10.6026/97320630015439 Abstract: Chikungunya virus (CHIKV) a re-emerging mosquito-borne alpha virus causes significant distress which is further accentuated in the lack of specific therapeutics or a preventive vaccine, mandating accelerated research for anti-CHIKV therapeutics. In recent years, drug repositioning has gained recognition for the curative interventions for its cost and time efficacy. CHIKV envelope proteins are considered to be the promising targets for drug discovery because of their essential role in viral attachment and entry in the host cells. In the current study, we propose structure-based virtual screening of drug molecule on the crystal structure of mature Chikungunya envelope protein (PDB 3N41) using a library of FDA approved drug molecules. Several cephalosporin drugs docked successfully within two binding sites prepared at E1-E2 interface of CHIKV envelop protein complex with significantly low binding energies. Cefmenoxime, ceforanide, cefotetan, cefonicid sodium and cefpiramide were identified as top leads with a cumulative score of -67.67, -64.90, -63.78, -61.99, and - 61.77, forming electrostatic, hydrogen and hydrophobic bonds within both the binding sites.
    [Show full text]
  • Download Download
    VOLUME 7 NOMOR 2 DESEMBER 2020 ISSN 2548 – 611X JURNAL BIOTEKNOLOGI & BIOSAINS INDONESIA Homepage Jurnal: http://ejurnal.bppt.go.id/index.php/JBBI IN SILICO STUDY OF CEPHALOSPORIN DERIVATIVES TO INHIBIT THE ACTIONS OF Pseudomonas aeruginosa Studi In Silico Senyawa Turunan Sefalosporin dalam Menghambat Aktivitas Bakteri Pseudomonas aeruginosa Saly Amaliacahya Aprilian*, Firdayani, Susi Kusumaningrum Pusat Teknologi Farmasi dan Medika, BPPT, Gedung LAPTIAB 610-612 Kawasan Puspiptek, Setu, Tangerang Selatan, Banten 15314 *Email: [email protected] ABSTRAK Infeksi yang diakibatkan oleh bakteri gram-negatif, seperti Pseudomonas aeruginosa telah menyebar luas di seluruh dunia. Hal ini menjadi ancaman terhadap kesehatan masyarakat karena merupakan bakteri yang multi-drug resistance dan sulit diobati. Oleh karena itu, pentingnya pengembangan agen antimikroba untuk mengobati infeksi semakin meningkat dan salah satu yang saat ini banyak dikembangkan adalah senyawa turunan sefalosporin. Penelitian ini melakukan studi mengenai interaksi tiga dimensi (3D) antara antibiotik dari senyawa turunan Sefalosporin dengan penicillin-binding proteins (PBPs) pada P. aeruginosa. Tujuan dari penelitian ini adalah untuk mengklarifikasi bahwa agen antimikroba yang berasal dari senyawa turunan sefalosporin efektif untuk menghambat aktivitas bakteri P. aeruginosa. Struktur PBPs didapatkan dari Protein Data Bank (PDB ID: 5DF9). Sketsa struktur turunan sefalosporin digambar menggunakan Marvins Sketch. Kemudian, studi mengenai interaksi antara antibiotik dan PBPs dilakukan menggunakan program Mollegro Virtual Docker 6.0. Hasil yang didapatkan yaitu nilai rerank score terendah dari kelima generasi sefalosporin, di antaranya sefalotin (-116.306), sefotetan (-133.605), sefoperazon (-160.805), sefpirom (- 144.045), dan seftarolin fosamil (-146.398). Keywords: antibiotik, penicillin-binding proteins, P. aeruginosa, sefalosporin, studi interaksi ABSTRACT Infections caused by gram-negative bacteria, such as Pseudomonas aeruginosa, have been spreading worldwide.
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Antibiotic Assay Medium No. 3 (Assay Broth) Is Used for Microbiological Assay of Antibiotics. M042
    HiMedia Laboratories Technical Data Antibiotic Assay Medium No. 3 (Assay Broth) is used for M042 microbiological assay of antibiotics. Antibiotic Assay Medium No. 3 (Assay Broth) is used for microbiological assay of antibiotics. Composition** Ingredients Gms / Litre Peptic digest of animal tissue (Peptone) 5.000 Beef extract 1.500 Yeast extract 1.500 Dextrose 1.000 Sodium chloride 3.500 Dipotassium phosphate 3.680 Potassium dihydrogen phosphate 1.320 Final pH ( at 25°C) 7.0±0.2 **Formula adjusted, standardized to suit performance parameters Directions Suspend 17.5 grams in 1000 ml distilled water. Heat if necessary to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Advice:Recommended for the Microbiological assay of Amikacin, Bacitracin, Capreomycin, Chlortetracycline,Chloramphenicol,Cycloserine,Demeclocycline,Dihydrostreptomycin, Doxycycline, Gentamicin, Gramicidin, Kanamycin, Methacycline, Neomycin, Novobiocin, Oxytetracycline, Rolitetracycline, Streptomycin, Tetracycline, Tobramycin, Trolendomycin and Tylosin according to official methods . Principle And Interpretation Antibiotic Assay Medium is used in the performance of antibiotic assays. Grove and Randall have elucidated those antibiotic assays and media in their comprehensive treatise on antibiotic assays (1). Antibiotic Assay Medium No. 3 (Assay Broth) is used in the microbiological assay of different antibiotics in pharmaceutical and food products by the turbidimetric method. Ripperre et al reported that turbidimetric methods for determining the potency of antibiotics are inherently more accurate and more precise than agar diffusion procedures (2). Turbidimetric antibiotic assay is based on the change or inhibition of growth of a test microorganims in a liquid medium containing a uniform concentration of an antibiotic. After incubation of the test organism in the working dilutions of the antibiotics, the amount of growth is determined by measuring the light transmittance using spectrophotometer.
    [Show full text]
  • 1028 Subpart A—Susceptibility Discs
    § 460.1 21 CFR Ch. I (4±1±96 Edition) 460.137 Methicillin concentrated stock solu- Neomycin: 30 mcg. tions for use in antimicrobial suscepti- Novobiocin: 30 mcg. bility test panels. Oleandomycin: 15 mcg. 460.140 Penicillin G concentrated stock so- Penicillin G: 10 units. lutions for use in antimicrobial suscepti- Polymyxin B: 300 units. bility test panels. Rifampin: 5 mcg. 460.146 Tetracycline concentrated stock so- Streptomycin: 10 mcg. lutions for use in antimicrobial suscepti- Tetracycline: 30 mcg. bility test panels. Tobramycin: 10 mcg. 460.149 Tobramycin concentrated stock so- Vancomycin: 30 mcg. lutions for use in antimicrobial suscepti- bility test panels. The standard discs used to determine 460.152 Trimethoprim concentrated stock the potency shall be made of paper as solutions for use in antimicrobial suscep- described in § 460.6(d). Each antibiotic tibility test panels. compound used to impregnate such 460.153 Sulfamethoxazole concentrated stock solutions for use in antimicrobial standard discs shall be equilibrated in susceptibility test panels. terms of the working standard des- ignated by the Commissioner for use in AUTHORITY: Sec. 507 of the Federal Food, determining the potency or purity of Drug, and Cosmetic Act (21 U.S.C. 357). such antibiotic. SOURCE: 39 FR 19181, May 30, 1974, unless (b) Packaging. The immediate con- otherwise noted. tainer shall be a tight container as de- fined by the U.S.P. and shall be of such Subpart AÐSusceptibility Discs composition as will not cause any change in the strength, quality, or pu- § 460.1 Certification procedures for an- rity of the contents beyond any limit tibiotic susceptibility discs.
    [Show full text]
  • 595 PART 441—PENEM ANTIBIOTIC DRUGS Subpart A—Bulk Drugs
    Food and Drug Administration, HHS § 441.20a (6) pH. Proceed as directed in § 436.202 imipenem per milliliter at 25 °C is ¶85° of this chapter, using an aqueous solu- to ¶95° on an anhydrous basis. tion containing 60 milligrams per mil- (vi) It gives a positive identity test. liliter. (vii) It is crystalline. (7) Penicillin G content. Proceed as di- (2) Labeling. It shall be labeled in ac- rected in § 436.316 of this chapter. cordance with the requirements of (8) Crystallinity. Proceed as directed § 432.5 of this chapter. in § 436.203(a) of this chapter. (3) Requests for certification; samples. (9) Heat stability. Proceed as directed In addition to complying with the re- in § 436.214 of this chapter. quirements of § 431.1 of this chapter, [42 FR 59873, Nov. 22, 1977; 43 FR 2393, Jan. 17, each such request shall contain: 1978, as amended at 45 FR 22922, Apr. 4, 1980; (i) Results of tests and assays on the 50 FR 19918, 19919, May 13, 1985] batch for potency, sterility, pyrogens, loss on drying, specific rotation, iden- PART 441ÐPENEM ANTIBIOTIC tity, and crystallinity. DRUGS (ii) Samples, if required by the Direc- tor, Center for Drug Evaluation and Subpart AÐBulk Drugs Research: (a) For all tests except sterility: 10 Sec. 441.20a Sterile imipenem monohydrate. packages, each containing approxi- mately 500 milligrams. Subpart BÐ[Reserved] (b) For sterility testing: 20 packages, each containing equal portions of ap- Subpart CÐInjectable Dosage Forms proximately 300 milligrams. 441.220 Imipenem monohydrate-cilastatin (b) Tests and methods of assayÐ(1) Po- sodium injectable dosage forms.
    [Show full text]